Trial Profile
A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Adenocarcinoma; Anal cancer; Cervical cancer; Cervical intraepithelial neoplasia; Condylomata acuminata; Gynaecological cancer; Human papillomavirus infections; Penile cancer
- Focus Pharmacodynamics; Registrational
- Sponsors Merck Sharp & Dohme
- 15 Jan 2024 New source identified and integrated European Union Clinical Trials Register: (EudraCT Number: 2023-001144-29)
- 09 Nov 2023 Status changed from active, no longer recruiting to completed.
- 22 Nov 2020 Primary endpoint (Geometric Mean Titers for Serum Anti-Human Papillomavirus (HPV) Types 6, 11, 16, and 18: Competitive Luminex Immunoassay (cLIA): Base Stage) has been met, according to results published in the Vaccine